Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Accelrys Slide 5 Percent on Flat Q4 Sales, Wider Losses

NEW YORK (GenomeWeb News) — Shares in Accelrys were down 5.3 percent, or $.35, at $6.21 in mid-afternoon trading after the company today posted weak fourth-quarter revenue growth and widened net loss.
 
As GenomeWeb News reported this morning, Accelrys said that total receipts for the three months ended Dec. 31, 2006, increased to $20.7 million from $20.4 million year over year. Losses nearly doubled to $1.1 million from $567,000 year over year.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.